<DOC>
	<DOCNO>NCT01798446</DOCNO>
	<brief_summary>- 1 . There standard treatment option non-clear cell renal cell carcinoma ( RCC ) . - 2 . Patients non-clear cell RCC strongly assume benefit anti-VEGF treatment . - 3 . There trial axitinib non-clear cell RCC . - 4 . Axitinib expect show potent efficacy sorafenib sunitinib renal cell carcinoma .</brief_summary>
	<brief_title>A Phase II Study Axitinib Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus</brief_title>
	<detailed_description>1 . Renal Cell Carcinoma Renal cell carcinoma malignant tumor occur frequently primary malignant tumor kidney.1 According Korea Central Cancer Registry ( KCCR ) data , renal cancer affect 4.4 100,000 male 2.1 100,000 female . About 30 % renal cancer patient accompany remote metastasis time diagnosis renal cancer even recur 40 % patient underwent surgery radical treatment renal cancer local disease.1 New treatment strategy renal cell carcinoma develop , obtain satisfactory therapeutic outcome . Thus , constant clinical study necessary improve therapeutic efficacy . 2 . Treatment Metastatic Renal Cell Carcinoma The treatment metastatic renal cell carcinoma improve lot recent year , , however , limit clear cell renal cell carcinoma . The drug show antitumor activity clear cell renal cell carcinoma include axitinib , sunitinib , sorafenib , bevacizumab , temsirolimus , everolimus . Of , axitinib , sunitinib , sorafenib , bevacizumab , etc . neovascularization inhibitor inhibit vascular endothelial growth factor ( VEGF ) receptor ( VEGFR ) . As first-line treatment , sunitinib prolongs progression-free survival ( PFS ) compare interferon-alpha , recognize first-line standard therapy . Sorafenib , second-line treatment , show significant prolongation PFS clear cell renal cell carcinoma compare placebo control group , establish second-line drug . Concomitantly administer interferon-alpha , bevacizumab show significant prolongation PFS compare single use interferon-alpha , establish another first-line therapy . Temsirolimus , mammalian target rapamycin ( mTOR ) inhibitor , extend survival time clinical study clear non-clear cell renal cell carcinoma . However , clinical study limit patient renal cell carcinoma bad prognostic factor . This renal cell carcinoma bad prognostic factor account 10-20 % entire metastatic renal cell carcinoma . Everolimus , another mTOR inhibitor , show significant prolongation PFS placebo-controlled phase III clinical study patient clear cell renal cell carcinoma sunitinib therapy fail , establish second-line therapy case first-line standard sunitinib therapy fail . 3 . Treatment Metastatic Non-clear Cell Renal Cell Carcinoma ( nccRCC ) In fact , VEGF antagonists show efficacy also nccRCC . Sunitinib effective nccRCC . A worldwide expand access trial sunitinib undertaken . A subgroup analysis patient non-clear-cell histology perform 276 patient ( 11.8 % ) non-clear-cell histology identify , although distinction different subtypes make . A response rate 5.4 % , clinical benefit ( define response stable disease 3 month ) 47 % median PFS 6.7 month see subgroup . This result compare overall response rate entire patient group 9.3 % , clinical benefit 52.3 % , median PFS 8.9 month . The investigator conclude sunitinib active non-clear-cell subgroup ; however , data need interpret caution nonrandomization patient expand access trial lack pathology verification . Also , recently , phase 2 trial sunitinib non-clear cell renal cell carcinoma show remarkable efficacy response rate 36 % median PFS 6.4 month . The study enrol non-clear cell RCC patient receive previous anti-angiogenic treatment . Sorafenib also show efficacy nccRCC , though efficacious . The Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program allow patient United States Canada metastatic RCC receive treatment sorafenib prior regulatory approval . This non-randomized , open-label program treat 158 subject papillary RCC total 1891 evaluable subject ( 81 % clear cell , 8 % non-clear , 11 % unclassified histology ) . Of 107 evaluable subject papillary RCC , 90 ( 84 % ) measurable response treatment 3 partial responder 87 stable disease least 8 week , 17 ( 16 % ) subject demonstrate early progression treatment . The side effect profile sorafenib similar across histologic subtypes , author conclude sorafenib activity papillary tumor . On hand , randomize phase 3 trial single-agent Axitinib 723 renal cell carcinoma patient progress despite first-line therapy contain sunitinib , bevacizumab plus interferon-alpha , temsirolimus cytokine , median PFS duration significantly longer axitinib sorafenib entire population ( 6.7 month versus 4.7 month , respectively : p le 0.0001 ) . 4 . Rationale In short , 1 . There standard treatment option non-clear cell RCC . 2 . Patients non-clear cell RCC strongly assume benefit anti-VEGF treatment . 3 . There trial axitinib non-clear cell RCC . 4 . Axitinib expect show potent efficacy sorafenib sunitinib renal cell carcinoma . Based , clinical study design examine efficacy adverse event axitinib non-clear cell renal cell carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically cytologically confirmation RCC without clear cell histologic component , e.g. , papillary type , chromophobe type , medullary type unclassified ) Patients stage IV recurrent disease amenable surgery , radiotherapy , combine modality therapy curative intent Previous treatment temsirolimus Measurable disease accord RECIST criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Age 18 year old Adequate cardiac function Adequate bone marrow , hepatic , renal function Hematology : Neutrophil 1.5 x 10^9/L Platelet 75 x 10^9/L Hemoglobin 9 g/dL Liver function test : Total bilirubin le 1.5 x upper limit normal ( xULN ) aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) less 2.5 xULN Alkaline phosphatase le 2.5 xULN Renal function test : Creatinine clearance 30 mL/min Life expectancy 3 month Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment Clear cell type RCC Composed mostly sarcomatoid carcinoma Collecting duct type RCC Diagnosis serious secondary malignancy within last 2 year , except adequately treat basal cell squamous cell carcinoma skin , situ carcinoma cervix uteri Hypertension control medication ( blood pressure 150/90 mmHg despite optimal medical therapy ) Pregnancy breast feed Other severe acute chronic medical psychiatric condition Prior treatment sunitinib , sorafenib , pazopanib bevacizumab Uncontrolled central nerve system ( CNS ) metastasis ( brain and/or leptomeningeal metastasis ) Patients require concomitant treatment potent cytochrome P 3A4 ( CYP3A4 ) inducer inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Nonclear cell</keyword>
	<keyword>Temsirolimus resistance</keyword>
</DOC>